Citations (71)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Pankaj Kumar Sharma, Nidhi Sandal & Meenakshi Kanwar Chauhan. (2021) Evaluation of precorneal residence time of brimonidine tartrate nanoparticles loaded in situ gel using gamma scintigraphy. Inorganic and Nano-Metal Chemistry 51:5, pages 701-708.
Read now
Read now
J. Skrzypecki, K. Ciepiaszuk & M. Gawryś-Kopczyńska. (2021) Low-dose Bevacizumab Decreases Ocular Hypotensive Effect of Angiotensin II in Sprague Dawley Rats. Current Eye Research 46:1, pages 127-134.
Read now
Read now
Nikola Sladojevic, Brian Yu & James K. Liao. (2017) ROCK as a therapeutic target for ischemic stroke. Expert Review of Neurotherapeutics 17:12, pages 1167-1177.
Read now
Read now
Jeffrey O’Callaghan, Paul S. Cassidy & Pete Humphries. (2017) Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway. Expert Opinion on Therapeutic Targets 21:11, pages 1037-1050.
Read now
Read now
Olivier Defert & Sandro Boland. (2017) Rho kinase inhibitors: a patent review (2014 – 2016). Expert Opinion on Therapeutic Patents 27:4, pages 507-515.
Read now
Read now
Jed Asher Lusthaus & Ivan Goldberg. (2016) Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma. Expert Opinion on Investigational Drugs 25:10, pages 1201-1208.
Read now
Read now
Kishore Cholkar, Hoang M Trinh, Dhananjay Pal & Ashim K Mitra. (2015) Discovery of novel inhibitors for the treatment of glaucoma. Expert Opinion on Drug Discovery 10:3, pages 293-313.
Read now
Read now
Sean K Wang & Robert T Chang. (2014) An emerging treatment option for glaucoma: Rho kinase inhibitors. Clinical Ophthalmology 8, pages 883-890.
Read now
Read now
Renu Agarwal & Puneet Agarwal. (2014) Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways. Expert Opinion on Therapeutic Targets 18:5, pages 527-539.
Read now
Read now
Pratap Challa & John J Arnold. (2014) Rho-kinase inhibitors offer a new approach in the treatment of glaucoma. Expert Opinion on Investigational Drugs 23:1, pages 81-95.
Read now
Read now
Irene Giorgi & Paola Nieri. (2013) Adenosine A1 modulators: a patent update (2008 to present). Expert Opinion on Therapeutic Patents 23:9, pages 1109-1121.
Read now
Read now
Baohe Tian & Paul L Kaufman. (2012) Comparisons of actin filament disruptors and Rho kinase inhibitors as potential antiglaucoma medications. Expert Review of Ophthalmology 7:2, pages 177-187.
Read now
Read now
Kenneth J Mandell, Matthew R Kudelka & Barbara Wirostko. (2011) Rho kinase inhibitors for treatment of glaucoma. Expert Review of Ophthalmology 6:6, pages 611-622.
Read now
Read now
Articles from other publishers (58)
Alexa DeMaio, Shikhar Mehrotra, Kumar Sambamurti & Shahid Husain. (2022) The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases. Journal of Neuroinflammation 19:1.
Crossref
Crossref
Zeqiu Yang, Jianbing Wu, Keling Wu, Jingyi Luo, Cunrui Li, Jiaming Zhang, Minglei Zhao, Tingfang Mei, Xinqi Liu, Bizhi Shang, Yihua Zhang, Ling Zhao & Zhangjian Huang. (2022) Identification of Nitric Oxide-Donating Ripasudil Derivatives with Intraocular Pressure Lowering and Retinal Ganglion Cell Protection Activities. Journal of Medicinal Chemistry 65:17, pages 11745-11758.
Crossref
Crossref
Shahin Hallaj, Mohammad Mirza-Aghazadeh-Attari, Amin Arasteh, Anahita Ghorbani, Daniel Lee & Farhad Jadidi-Niaragh. (2021) Adenosine: The common target between cancer immunotherapy and glaucoma in the eye. Life Sciences 282, pages 119796.
Crossref
Crossref
Benjamin Brennecke, Thais Gazzi, Kenneth Atz, Jürgen Fingerle, Pascal Kuner, Torsten Schindler, Guy de Weck, Marc Nazaré & Uwe Grether. (2021) Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010. Pharmaceutical Patent Analyst 10:3, pages 111-163.
Crossref
Crossref
Raffaele Nuzzi, Paola Marolo & Alessia Nuzzi. (2021) What Is New in Glaucoma: From Treatment to Biological Perspectives. Journal of Ophthalmology 2021, pages 1-10.
Crossref
Crossref
Makoto Araie, Kazuhisa Sugiyama, Kenji Aso, Koji Kanemoto, Kalyani Kothapalli, Casey Kopczynski, Michelle Senchyna & David A. Hollander. (2021) Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. Advances in Therapy 38:4, pages 1757-1775.
Crossref
Crossref
Eleonora Spinozzi, Cecilia Baldassarri, Laura Acquaticci, Fabio Del Bello, Mario Grifantini, Loredana Cappellacci & Petrelli Riccardo. (2021) Adenosine receptors as promising targets for the management of ocular diseases. Medicinal Chemistry Research 30:2, pages 353-370.
Crossref
Crossref
D. Anitha, M. Suganthi, S. Gnanendra & M. Govarthanan. (2020) Identification of Potential Carbonic Anhydrase Inhibitors for Glaucoma Treatment Through an In-Silico Approach. International Journal of Peptide Research and Therapeutics 26:4, pages 2147-2154.
Crossref
Crossref
Kuei-Ju Cheng, Chien-Ming Hsieh, Kunal Nepali & Jing-Ping Liou. (2020) Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye. Journal of Medicinal Chemistry 63:19, pages 10533-10593.
Crossref
Crossref
Graziella Ribeiro de Sousa, Gabriela Maciel Vieira, Pablo Ferreira das Chagas, Julia Alejandra Pezuk & María Sol Brassesco. (2020) Should we keep rocking? Portraits from targeting Rho kinases in cancer. Pharmacological Research 160, pages 105093.
Crossref
Crossref
Vasudha Abbhi & Poonam Piplani. (2020) Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility. Current Medicinal Chemistry 27:14, pages 2222-2256.
Crossref
Crossref
Soumajit Ghorai, Sravani Pulya, Kalyan Ghosh, Parthasarathi Panda, Balaram Ghosh & Shovanlal Gayen. (2020) Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents. Bioorganic Chemistry 95, pages 103557.
Crossref
Crossref
Guido Furlotti, Maria Alessandra Alisi, Nicola Cazzolla, Francesca Ceccacci, Beatrice Garrone, Tecla Gasperi, Angela La Bella, Francesca Leonelli, Maria Antonietta Loreto, Gabriele Magarò, Giorgina Mangano, Rinaldo Marini Bettolo, Emanuela Masini, Martina Miceli, Luisa Maria Migneco & Marco Vitiello. (2018)
Targeting Serotonin 2A and Adrenergic α
1
Receptors for Ocular Antihypertensive Agents: Discovery of 3,4‐Dihydropyrazino[1,2‐
b
]indazol‐1(2
H
)‐one Derivatives
. ChemMedChem 13:15, pages 1597-1607.
Crossref
Crossref
Ralph J. Hazlewood, Qingxia Chen, Frances K. Clark, John Kuchtey & Rachel W. Kuchtey. (2018) Differential effects of angiotensin II type I receptor blockers on reducing intraocular pressure and TGFβ signaling in the mouse retina. PLOS ONE 13:8, pages e0201719.
Crossref
Crossref
Ke Wang, Guorong Li, A. Thomas Read, Iris Navarro, Ashim K. Mitra, W. Daniel Stamer, Todd Sulchek & C. Ross Ethier. (2018) The relationship between outflow resistance and trabecular meshwork stiffness in mice. Scientific Reports 8:1.
Crossref
Crossref
Xin Zhang, Xiuting Liu, Wei Zhou, Mengdi Yang, Yang Ding, Qing Wang & Rong Hu. (2018) Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. Cell Death & Disease 9:2.
Crossref
Crossref
Vanessa Andrés-Guerrero, Irene Bravo-Osuna, Pilar Pastoriza, Irene T. Molina-Martinez & Rocío Herrero-Vanrell. (2017) Novel technologies for the delivery of ocular therapeutics in glaucoma. Journal of Drug Delivery Science and Technology 42, pages 181-192.
Crossref
Crossref
Mohammad Pakravan, Afsaneh Naderi Beni, Elham Ghahari, Reyhaneh Varshochian, Shahin Yazdani, Hamed Esfandiari & Hamid Ahmadieh. (2017) The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma. American Journal of Therapeutics 24:6, pages e676-e680.
Crossref
Crossref
Raffaele Nuzzi & Federico Tridico. (2017) Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis. Frontiers in Neuroscience 11.
Crossref
Crossref
Almudena Crooke, Fernando Huete-Toral, Basilio Colligris & Jesús Pintor. (2017) The role and therapeutic potential of melatonin in age-related ocular diseases. Journal of Pineal Research 63:2, pages e12430.
Crossref
Crossref
Vanessa Andrés-Guerrero, Julián García-Feijoo & Anastasios Georgios Konstas. (2017) Targeting Schlemm’s Canal in the Medical Therapy of Glaucoma: Current and Future Considerations. Advances in Therapy 34:5, pages 1049-1069.
Crossref
Crossref
Gurjeet Jutley, Sheila MH Luk, Mohammad H Dehabadi & M Francesca Cordeiro. (2017) Management of glaucoma as a neurodegenerative disease. Neurodegenerative Disease Management 7:2, pages 157-172.
Crossref
Crossref
Yangbo Feng, Philip V. LoGrasso, Olivier Defert & Rongshi Li. (2015) Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential. Journal of Medicinal Chemistry 59:6, pages 2269-2300.
Crossref
Crossref
Jose M. Gonzalez, Minhee K. Ko, Andrew Pouw & James C. H. Tan. (2016) Tissue-based multiphoton analysis of actomyosin and structural responses in human trabecular meshwork. Scientific Reports 6:1.
Crossref
Crossref
Rebecca K. Donegan & Raquel L. Lieberman. (2015) Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions. Journal of Medicinal Chemistry 59:3, pages 788-809.
Crossref
Crossref
Kristi R. Chakrabarti, Lindsay Hessler, Lekhana Bhandary & Stuart S. Martin. (2015) Molecular Pathways: New Signaling Considerations When Targeting Cytoskeletal Balance to Reduce Tumor Growth. Clinical Cancer Research 21:23, pages 5209-5214.
Crossref
Crossref
Wei-Sheng Chen, Zhiyi Cao, Chandrasekharan Krishnan & Noorjahan Panjwani. (2015) Verteporfin without light stimulation inhibits YAP activation in trabecular meshwork cells: Implications for glaucoma treatment. Biochemical and Biophysical Research Communications 466:2, pages 221-225.
Crossref
Crossref
S. M. Thomasy & M. Lassaline. (2015) Equine glaucoma: Where are we now?. Equine Veterinary Education 27:8, pages 420-429.
Crossref
Crossref
Sarah Van de Velde, Lies De Groef, Ingeborg Stalmans, Lieve Moons & Inge Van Hove. (2015) Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics. Progress in Neurobiology 131, pages 105-119.
Crossref
Crossref
Kolko M. (2015) Present and New Treatment Strategies in the Management of Glaucoma. The Open Ophthalmology Journal 9:1, pages 89-100.
Crossref
Crossref
Najam A. Sharif. (2015) Novel Potential Treatment Modalities for Ocular Hypertension: Focus on Angiotensin and Bradykinin System Axes. Journal of Ocular Pharmacology and Therapeutics 31:3, pages 131-145.
Crossref
Crossref
Qinhua Huang, Eugene Y. Rui, Morena Cobbs, Dac M. Dinh, Hovhannes J. Gukasyan, Jennifer A. Lafontaine, Saurabh Mehta, Brian D. Patterson, David A. Rewolinski, Paul F. Richardson & Martin P. Edwards. (2015) Design, Synthesis, and Evaluation of NO-Donor Containing Carbonic Anhydrase Inhibitors To Lower Intraocular Pressure. Journal of Medicinal Chemistry 58:6, pages 2821-2833.
Crossref
Crossref
Karthik Dhananjayan, Sumathy Arunachalam, Palanisamy Sivanandy & Manojkumar Parameswaran. (2014) Computational drug discovery of Rho – associated coiled coil kinase II (ROCK-II) inhibitors as a target for neurodegenerative disorders – an insilico docking studies. Oriental Pharmacy and Experimental Medicine 15:1, pages 53-71.
Crossref
Crossref
W. Daniel Stamer, Sietse T. Braakman, Enhua H. Zhou, C. Ross Ethier, Jeffrey J. Fredberg, Darryl R. Overby & Mark Johnson. (2015) Biomechanics of Schlemm's canal endothelium and intraocular pressure reduction. Progress in Retinal and Eye Research 44, pages 86-98.
Crossref
Crossref
Yeni Yucel & Neeru Gupta. 2015. New Trends in Basic and Clinical Research of Glaucoma: A Neurodegenerative Disease of the Visual System, Part A. New Trends in Basic and Clinical Research of Glaucoma: A Neurodegenerative Disease of the Visual System, Part A
185
198
.
Carol A. Rasmussen & Paul L. Kaufman. (2014) Exciting directions in glaucoma. Canadian Journal of Ophthalmology 49:6, pages 534-543.
Crossref
Crossref
Kaitlin C. Murphy, Joshua T. Morgan, Joshua A. Wood, Adeline Sadeli, Christopher J. Murphy & Paul Russell. (2014) The formation of cortical actin arrays in human trabecular meshwork cells in response to cytoskeletal disruption. Experimental Cell Research 328:1, pages 164-171.
Crossref
Crossref
Musarrat H. Warsi, Mohammed Anwar, Vaidehi Garg, Gaurav K. Jain, Sushama Talegaonkar, Farhan J. Ahmad & Roop K. Khar. (2014) Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: Pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits. Colloids and Surfaces B: Biointerfaces 122, pages 423-431.
Crossref
Crossref
Darryl R. OverbyEnhua H. ZhouRocio Vargas-PintoRyan M. PedrigiRudolf FuchshoferSietse T. BraakmanRitika GuptaKristin M. PerkumasJoseph M. SherwoodAmir VahabikashiQuynh DangJae Hun KimC. Ross EthierW. Daniel Stamer, Jeffrey J. FredbergMark Johnson. (2014) Altered mechanobiology of Schlemm’s canal endothelial cells in glaucoma. Proceedings of the National Academy of Sciences 111:38, pages 13876-13881.
Crossref
Crossref
Emmanuel S. Buys, Lincoln R. Potter, Louis R. Pasquale & Bruce R. Ksander. (2014) Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma. Frontiers in Molecular Neuroscience 7.
Crossref
Crossref
Haiyan GongChen-Yuan Charlie Yang. (2014) Morphological and Hydrodynamic Correlations with Increasing Outflow Facility by Rho-Kinase Inhibitor Y-27632. Journal of Ocular Pharmacology and Therapeutics 30:2-3, pages 143-153.
Crossref
Crossref
John KuchteyRachel W. Kuchtey. (2014) The Microfibril Hypothesis of Glaucoma: Implications for Treatment of Elevated Intraocular Pressure. Journal of Ocular Pharmacology and Therapeutics 30:2-3, pages 170-180.
Crossref
Crossref
Tsontcho Ianchulev. 2014. Surgical Innovations in Glaucoma. Surgical Innovations in Glaucoma
33
43
.
Tsutomu Akama, Chen Dong, Charlotte Virtucio, David Sullivan, Yasheen Zhou, Yong-Kang Zhang, Fernando Rock, Yvonne Freund, Liang Liu, Wei Bu, Anne Wu, Xiao-Qing Fan & Kurt Jarnagin. (2013) Linking Phenotype to Kinase: Identification of a Novel Benzoxaborole Hinge-Binding Motif for Kinase Inhibition and Development of High-Potency Rho Kinase Inhibitors. Journal of Pharmacology and Experimental Therapeutics 347:3, pages 615-625.
Crossref
Crossref
Peichen Pan, Mingyun Shen, Huidong Yu, Youyong Li, Dan Li & Tingjun Hou. (2013) Advances in the development of Rho-associated protein kinase (ROCK) inhibitors. Drug Discovery Today 18:23-24, pages 1323-1333.
Crossref
Crossref
Karen Y. Torrejon, Dennis Pu, Magnus Bergkvist, John Danias, Susan T. Sharfstein & Yubing Xie. (2013) Recreating a human trabecular meshwork outflow system on microfabricated porous structures. Biotechnology and Bioengineering 110:12, pages 3205-3218.
Crossref
Crossref
Dharani Manickavasagam & Moses O. Oyewumi. (2013) Critical Assessment of Implantable Drug Delivery Devices in Glaucoma Management. Journal of Drug Delivery 2013, pages 1-12.
Crossref
Crossref
Nello Mainolfi, James Powers, Jakal Amin, Debby Long, Wendy Lee, Margaret E. McLaughlin, Bruce Jaffee, Christopher Brain, Jason Elliott & Jeremy M. Sivak. (2013)
An Effective Prodrug Strategy to Selectively Enhance Ocular Exposure of a Cannabinoid Receptor (CB
1/2
) Agonist
. Journal of Medicinal Chemistry 56:13, pages 5464-5472.
Crossref
Crossref
A. Rocha-Sousa, J. Rodrigues-Araújo, Petra Gouveia, João Barbosa-Breda, S. Azevedo-Pinto, P. Pereira-Silva & A. Leite-Moreira. (2013) New Therapeutic Targets for Intraocular Pressure Lowering. ISRN Ophthalmology 2013, pages 1-14.
Crossref
Crossref
Yisheng Zhong, Zijian Yang, Wei-Chieh Huang & Xunda Luo. (2013) Adenosine, adenosine receptors and glaucoma: An updated overview. Biochimica et Biophysica Acta (BBA) - General Subjects 1830:4, pages 2882-2890.
Crossref
Crossref
Emmanuel S. Buys, Yu-Chieh Ko, Clemens Alt, Sarah R. Hayton, Alexander Jones, Laurel T. Tainsh, Ruiyi Ren, Andrea Giani, Maeva Clerté, Emma Abernathy, Robert E. T. Tainsh, Dong-Jin Oh, Rajeev Malhotra, Pankaj Arora, Nadine de Waard, Binglan Yu, Raphael Turcotte, Daniel Nathan, Marielle Scherrer-Crosbie, Stephanie J. Loomis, Jae H. Kang, Charles P. Lin, Haiyan Gong, Douglas J. Rhee, Peter Brouckaert, Janey L. Wiggs, Meredith S. Gregory, Louis R. Pasquale, Kenneth D. Bloch & Bruce R. Ksander. (2013) Soluble Guanylate Cyclase α1–Deficient Mice: A Novel Murine Model for Primary Open Angle Glaucoma. PLoS ONE 8:3, pages e60156.
Crossref
Crossref
Claudio Bucolo, Salvatore Salomone, Filippo Drago, Michele Reibaldi, Antonio Longo & Maurizio Giacinto Uva. (2013) Pharmacological management of ocular hypertension: current approaches and future prospective. Current Opinion in Pharmacology 13:1, pages 50-55.
Crossref
Crossref
Mingyun Shen, Huidong Yu, Youyong Li, Pixu Li, Peichen Pan, Shunye Zhou, Liling Zhang, Shang Li, Simon Ming-Yuen Lee & Tingjun Hou. (2013) Discovery of Rho-kinase inhibitors by docking-based virtual screening. Molecular BioSystems 9:6, pages 1511.
Crossref
Crossref
Mingyun Shen, Shunye Zhou, Youyong Li, Peichen Pan, Liling Zhang & Tingjun Hou. (2013) Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations. Molecular BioSystems 9:3, pages 361.
Crossref
Crossref
Sara McNally & Colm J. O’Brien. (2013) Drug discovery in glaucoma and the role of animal models. Drug Discovery Today: Disease Models 10:4, pages e207-e214.
Crossref
Crossref
Kang Zhang, Liangfang Zhang & Robert N. Weinreb. (2012) Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nature Reviews Drug Discovery 11:7, pages 541-559.
Crossref
Crossref
Ingrida Januleviciene, Lina Siaudvytyte & Ruta Barsauskaite. (2012) Ophthalmic Drug Delivery in Glaucoma—A Review. Pharmaceutics 4:1, pages 243-251.
Crossref
Crossref
W. Daniel Stamer & Ted S. Acott. (2012) Current understanding of conventional outflow dysfunction in glaucoma. Current Opinion in Ophthalmology 23:2, pages 135-143.
Crossref
Crossref